Table 4.

Noncardiovascular Immune-Related Adverse Events

Organ System	Immune-Related Adverse Events60,158, 159, 160	Estimated Incidence
Skin	Maculopapular rash, pruritis, vitiligo-like lesions, erythema multiforme, lichenoid, eczematous, psoriasiform, morbilliform, palmar-plantar erythrodysesthesia, bullous dermatoses, hand-foot syndrome	Overall: 71.5% Maculopapular rash: 14%-24%
Gastrointestinal	Immune-related diarrhea, colitis, hepatitis, gastritis, enterocolitis	Diarrhea: 25%-54% Colitis: 3% Hepatitis: 10%-30%
Endocrine	Hypothyroidism, hyperthyroidism, primary adrenal insufficiency, hypophysitis, diabetes	Hypothyroidism: 6.6% Hyperthyroidism: 2.9% Primary adrenal insufficiency: 0.7% Hypophysitis: 1.3%
Lung	Pneumonitis	2.7%-10%
Musculoskeletal	Arthralgia, myalgia, inflammatory arthritis, myositis, polymyalgia-like syndrome	Arthralgia or myalgia: 40%
Renal	Nephritis, acute kidney injury	Acute kidney injury: 1%-5%
Neurological	Headache, myasthenia gravis or myasthenic syndrome, aseptic meningitis, encephalitis, Guillain-Barré syndrome, peripheral neuropathy, demyelinating disorders	Overall: 3%-12% High-grade: <1%
Hematologic	Hemolytic anemia, acquired thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, aplastic anemia, lymphopenia, immune thrombocytopenia	Anemia: 9.8% Thrombocytopenia: 2.8%
Ocular	Uveitis, iritis, episcleritis	Uveitis: 1% Episcleritis: <1%

Incidences provided are for both monotherapy and combination immune checkpoint inhibitor regimens.